EML4-ALK: honing in on a new target in non-small-cell lung cancer.
作者信息
Horn Leora, Pao William
出版信息
J Clin Oncol. 2009 Sep 10;27(26):4232-5. doi: 10.1200/JCO.2009.23.6661. Epub 2009 Aug 10.
Abstract
摘要
相似文献
1
EML4-ALK: honing in on a new target in non-small-cell lung cancer.
J Clin Oncol. 2009 Sep 10;27(26):4232-5. doi: 10.1200/JCO.2009.23.6661. Epub 2009 Aug 10.
2
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.
3
EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer.
Oncology. 2012;83(5):248-56. doi: 10.1159/000341381. Epub 2012 Sep 4.
4
A survey of Japanese thoracic oncologists' perception of diagnostic and treatment strategies for EGFR mutant or EML4-ALK fusion non-small cell lung cancer.
Chest. 2014 Dec;146(6):e222-e225. doi: 10.1378/chest.14-2055.
5
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
Oncotarget. 2016 Jan 5;7(1):1066-75. doi: 10.18632/oncotarget.6279.
6
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
Cancer. 2009 Apr 15;115(8):1723-33. doi: 10.1002/cncr.24181.
7
The biology and treatment of EML4-ALK non-small cell lung cancer.
Eur J Cancer. 2010 Jul;46(10):1773-80. doi: 10.1016/j.ejca.2010.04.002. Epub 2010 Apr 24.
8
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
J Thorac Oncol. 2012 Jan;7(1):98-104. doi: 10.1097/JTO.0b013e3182370e30.
9
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
Clin Lung Cancer. 2016 Nov;17(6):602-605. doi: 10.1016/j.cllc.2016.05.005. Epub 2016 Jun 2.
10
Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Arch Pathol Lab Med. 2012 Jul;136(7):796-803. doi: 10.5858/arpa.2011-0321-OA.
引用本文的文献
1
Lung Adenocarcinoma Expressing an EML4-ALK Fusion Transcript With Premature Stop Codons and Response to Alectinib: A Case Report.
Thorac Cancer. 2025 Aug;16(15):e70146. doi: 10.1111/1759-7714.70146.
2
Rare sequential EGFR and ALK mutations in non-small cell lung cancer: A case report and literature review.
Oncol Lett. 2025 Jun 18;30(2):398. doi: 10.3892/ol.2025.15144. eCollection 2025 Aug.
3
Prevalence of Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study.
Lung Cancer (Auckl). 2025 Apr 21;16:39-49. doi: 10.2147/LCTT.S494554. eCollection 2025.
4
RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer.
Signal Transduct Target Ther. 2025 Apr 18;10(1):124. doi: 10.1038/s41392-025-02206-x.
5
Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis.
Front Pharmacol. 2024 Sep 27;15:1361443. doi: 10.3389/fphar.2024.1361443. eCollection 2024.
6
Treatment Advances in Lung Cancer with Leptomeningeal Metastasis.
Curr Cancer Drug Targets. 2024;24(9):910-919. doi: 10.2174/0115680096276133231201061114.
7
Recent advances in molecular targeted therapy of lung cancer: Possible application in translation medicine.
Iran J Basic Med Sci. 2024;27(2):122-133. doi: 10.22038/IJBMS.2023.72407.15749.
8
Liquid‒liquid phase separation: roles and implications in future cancer treatment.
Int J Biol Sci. 2023 Aug 6;19(13):4139-4156. doi: 10.7150/ijbs.81521. eCollection 2023.
9
Case report: Concomitant mutation and rearrangement in non-small cell lung cancer.
Front Pharmacol. 2023 Aug 29;14:1167959. doi: 10.3389/fphar.2023.1167959. eCollection 2023.
10
New insights into the important roles of phase seperation in the targeted therapy of lung cancer.
Cell Biosci. 2023 Aug 14;13(1):150. doi: 10.1186/s13578-023-01101-8.
本文引用的文献
1
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.
2
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.
Clin Cancer Res. 2009 May 1;15(9):3143-9. doi: 10.1158/1078-0432.CCR-08-3248. Epub 2009 Apr 21.
3
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
Mod Pathol. 2009 Apr;22(4):508-15. doi: 10.1038/modpathol.2009.2. Epub 2009 Feb 20.
4
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
Cancer. 2009 Apr 15;115(8):1723-33. doi: 10.1002/cncr.24181.
5
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
Am J Pathol. 2009 Feb;174(2):661-70. doi: 10.2353/ajpath.2009.080755. Epub 2009 Jan 15.
6
A mouse model for EML4-ALK-positive lung cancer.
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7. doi: 10.1073/pnas.0805381105. Epub 2008 Dec 8.
7
Somatic mutations affect key pathways in lung adenocarcinoma.
Nature. 2008 Oct 23;455(7216):1069-75. doi: 10.1038/nature07423.
8
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
Clin Cancer Res. 2008 Oct 15;14(20):6618-24. doi: 10.1158/1078-0432.CCR-08-1018.
9
Activating mutations in ALK provide a therapeutic target in neuroblastoma.
Nature. 2008 Oct 16;455(7215):975-8. doi: 10.1038/nature07397.
10
Oncogenic mutations of ALK kinase in neuroblastoma.
Nature. 2008 Oct 16;455(7215):971-4. doi: 10.1038/nature07399.
Zotero 插件